Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss
He has spent more than a decade evaluating sarcopenic obesity, a condition he says is underrecognized
SURPASS-CVOT meanwhile, provided new evidence on the cardiovascular benefits of tirzepatide, although conducted in a type 2 diabetes population and comparing tirzepatide to dulaglutide [7]
In other words, its when the thyroid is underactive. For many women, the root cause of hypothyroidism is Hashimotos thyroiditis, an autoimmune condition where the body attacks its own thyroid tissue
Aleem A, Kothadia JP (2021) Remdesivir